SEC Form 4 · accession 0001662252-16-000305
Xenetic Biosciences, Inc. · XBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Michael Scott Maguire
Officer — CEO · Director
Period of report
Dec 20, 2016
Accepted (ET)
Dec 23, 2016 · 2:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534525
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $3.50 | Dec 20, 2016 | A | 83,334 | A | Dec 20, 2017 | Dec 20, 2026 | Common Stock | 83,334 | 277,120 | D |
| Stock OptionF1 | $3.50 | Dec 20, 2016 | A | 83,333 | A | Dec 20, 2018 | Dec 20, 2026 | Common Stock | 83,333 | 360,453 | D |
| Stock OptionF1 | $3.50 | Dec 20, 2016 | A | 83,333 | A | Dec 20, 2019 | Dec 20, 2026 | Common Stock | 83,333 | 443,786 | D |
Explanation of responses
- F1On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 250,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. The Option has a ten-year life and vests one-third upon the first anniversary of the grant date, one-third upon the second anniversary of the grant date and one-third on the third anniversary of the grant date.